Abstract
Lung cancer and breast cancer are diseases with fundamentally different clinical presentation, symptom burden, treatment options, life expectancy, and palliative needs. Most patients with lung cancer present with advanced, symptomatic disease. The great majority of these patients cannot be cured, and they have limited treatment options. Except for a few patients with molecular targets for drugs, they have to rely on chemotherapy and radiotherapy, which only marginally improve survival and are primarily used to ameliorate symptoms and delay disease progression. Patients should be offered palliative care as soon as the cancer is considered incurable. If comprehensive palliative care is put into effect this early, it not only improves the patients’ well-being but may prolong survival. In contrast, most women with breast cancer present with a localized, curable disease. If they develop metastatic disease, they cannot be cured, just like patients with lung cancer, but they face many more treatment options. Median life expectancy is about twice as long as for lung cancer. The cancer itself and cancer-associated symptoms can be controlled in many women for a prolonged period of time. Patients thus face a long-standing, chronic course with a series of relapses and re-treatments. This may result in a feeling of unlimited treatment options and necessarily leads to disappointment when treatment options dwindle. Palliative caregivers should know the differences between patients’ characteristics, treatment options, and the effect of treatment on patients’ expectations to provide optimal support.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
This manuscript is limited to women with breast cancer. Men comprise only about 1 % of patients with breast cancer, and data and recommendations are derived from small series and expert opinion.
References
Aberle DR, Abtin F, Brown K (2013) Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial. J Clin Oncol 31:1002–1008
Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Hu JC, Nguyen PL (2013) Marital status and survival in patients with cancer. J Clin Oncol 31:3869–3876
Alt-Epping B, Staritz AE, Simon ST, Altfelder N, Hotz T, Lindena G, Nauck F (2012) What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey. J Palliat Med 15:971–977
Amann E, Huang DJ, Weber WP, Eppenberger-Castori S, Schmid SM, Hess TH, Guth U (2013) Disease-related surgery in patients with distant metastatic breast cancer. Eur J Surg Oncol 39:1192–1198
Aranda S, Schofield P, Weih L, Yates P, Milne D, Faulkner R, Voudouris N (2005) Mapping the quality of life and unmet needs of urban women with metastatic breast cancer. Eur J Cancer Care (Engl) 14:211–222
Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le CT, Le PC, Parmar MK, Pignon JP, Souhami RL, Stephens RJ, Stewart LA, Tierney JF, Tribodet H, van Meerbeeck J (2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 375:1267–1277
Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119
Bridges JF, Mohamed AF, Finnern HW, Woehl A, Hauber AB (2012) Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer 77:224–231
Buettner R, Wolf J, Thomas RK (2013) Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 31:1858–1865
Burns CM, Broom DH, Smith WT, Dear K, Craft PS (2007) Fluctuating awareness of treatment goals among patients and their caregivers: a longitudinal study of a dynamic process. Support Care Cancer 15:187–196
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di LA, El SN, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, Van’t Veer L, Viale G, Krop I, Winer E (2012a) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 21:242–252
Cardoso F, Loibl S, Pagani O, Graziottin A, Panizza P, Martincich L, Gentilini O, Peccatori F, Fourquet A, Delaloge S, Marotti L, Penault-Llorca F, Kotti-Kitromilidou AM, Rodger A, Harbeck N (2012b) The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 48:3355–3377
Chapple A, Ziebland S, McPherson A (2004) Stigma, shame, and blame experienced by patients with lung cancer: qualitative study. BMJ 328:1470
Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377:127–138
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 15:23–34
de Jong WK, ten Hacken NH, Groen HJ (2006) Third-line chemotherapy for small cell lung cancer. Lung Cancer 52:339–342
De la Torre-Diez I, Diaz-Pernas FJ, Anton-Rodriguez M (2012) A content analysis of chronic diseases social groups on Facebook and Twitter. Telemed J E Health 18:404–408
De Marinis F, Pereira JR, Fossella F, Perry MC, Reck M, Salzberg M, Jassem J, Peterson P, Liepa AM, Moore P, Gralla RJ (2008) Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 3:30–36
Desantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64:52–62
el Saghir NS, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A (2011) Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol 80:433–449
Ford DW, Koch KA, Ray DE, Selecky PA (2013) Palliative and end-of-life care in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143:e498S–e512S
Gaertner J, Wolf J, Scheicht D, Frechen S, Klein U, Hellmich M, Ostgathe C, Hallek M, Voltz R (2010) Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility project. J Palliat Med 13:727–732
Gaertner J, Wolf J, Frechen S, Klein U, Scheicht D, Hellmich M, Toepelt K, Glossmann JP, Ostgathe C, Hallek M, Voltz R (2012) Recommending early integration of palliative care – does it work? Support Care Cancer 20:507–513
Geels P, Eisenhauer E, Bezjak A, Zee B, Day A (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18:2395–2405
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2:706–714
Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205
Gripp S, Moeller S, Bolke E, Schmitt G, Matuschek C, Asgari S, Asgharzadeh F, Roth S, Budach W, Franz M, Willers R (2007) Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 25:3313–3320
Grunfeld EA, Maher EJ, Browne S, Ward P, Young T, Vivat B, Walker G, Wilson C, Potts HW, Westcombe AM, Richards MA, Ramirez AJ (2006) Advanced breast cancer patients’ perceptions of decision making for palliative chemotherapy. J Clin Oncol 24:1090–1098
Harris JR, Lippman ME, Osborne CK, Morrow M (2009) Diseases of the breast. Lippincott Williams & Wilkins, Philadelphia
Hoffe S, Balducci L (2012) Cancer and age: general considerations. Clin Geriatr Med 28:1–18
Hopwood P, Stephens RJ (1995) Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer 71:633–636
Ignatius Ou SH, Zell JA (2009) The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol 4:300–310
Irvin W Jr, Muss HB, Mayer DK (2011) Symptom management in metastatic breast cancer. Oncologist 16:1203–1214
Kenne SE, Ohlen J, Jonsson T, Gaston-Johansson F (2007) Coping with recurrent breast cancer: predictors of distressing symptoms and health-related quality of life. J Pain Symptom Manage 34:24–39
Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, Meadows AT, Friedman D, Robison LL, Diller L (2004) Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 141:590–597
Kiely BE, Soon YY, Tattersall MH, Stockler MR (2011) How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29:456–463
Koczywas M, Cristea M, Thomas J, McCarty C, Borneman T, Del FC, Sun V, Uman G, Ferrell B (2013) Interdisciplinary palliative care intervention in metastatic non-small-cell lung cancer. Clin Lung Cancer 14:736–744
Lam WW, Au AH, Wong JH, Lehmann C, Koch U, Fielding R, Mehnert A (2011) Unmet supportive care needs: a cross-cultural comparison between Hong Kong Chinese and German Caucasian women with breast cancer. Breast Cancer Res Treat 130:531–541
Larsen PB, Kumler I, Nielsen DL (2013) A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treat Rev 39:720–727
Lester JF, Agulnik J, Akerborg O, Chouaid C, De GA, Finnern HW, Herder GJ, Lungershausen J, Mitchell PL, Vansteenkiste J, Ziske C, Goker E (2013) What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?–results from the lung cancer economics and outcomes research (LUCEOR) study. Lung Cancer 82:128–135
LoConte NK, Else-Quest NM, Eickhoff J, Hyde J, Schiller JH (2008) Assessment of guilt and shame in patients with non-small-cell lung cancer compared with patients with breast and prostate cancer. Clin Lung Cancer 9:171–178
Luoma ML, Hakamies-Blomqvist L (2004) The meaning of quality of life in patients being treated for advanced breast cancer: a qualitative study. Psychooncology 13:729–739
Lutz S, Norrell R, Bertucio C, Kachnic L, Johnson C, Arthur D, Schwarz M, Palardy G (2001) Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital. J Palliat Med 4:157–165
Mack JW, Smith TJ (2012) Reasons why physicians do not have discussions about poor prognosis, why it matters, and what can be improved. J Clin Oncol 30:2715–2717
Marlow LA, Waller J, Wardle J (2010) Variation in blame attributions across different cancer types. Cancer Epidemiol Biomarkers Prev 19:1799–1805
Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, le Chevalier T, Fossella F, Herbst RS (2003) A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39:55–61
Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24:3490–3496
Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100:1780–1791
Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Douglas F, Hodgson S, Walker L, Porteous ME, Morrison PJ, Side LE, Kennedy MJ, Houghton C, Donaldson A, Rogers MT, Dorkins H, Miedzybrodzka Z, Gregory H, Eason J, Barwell J, McCann E, Murray A, Antoniou AC, Easton DF (2013) Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 105:812–822
Mayer M (2010) Lessons learned from the metastatic breast cancer community. Semin Oncol Nurs 26:195–202
Meraviglia MG (2004) The effects of spirituality on well-being of people with lung cancer. Oncol Nurs Forum 31:89–94
Morrogh M, Miner TJ, Park A, Jenckes A, Gonen M, Seidman A, Morrow M, Jaques DP, King TA (2010) A prospective evaluation of the durability of palliative interventions for patients with metastatic breast cancer. Cancer 116:3338–3347
Murray SA, Kendall M, Boyd K, Worth A, Benton TF (2004) Exploring the spiritual needs of people dying of lung cancer or heart failure: a prospective qualitative interview study of patients and their carers. Palliat Med 18:39–45
Okuyama T, Akechi T, Yamashita H, Toyama T, Nakaguchi T, Uchida M, Furukawa TA (2011) Oncologists’ recognition of supportive care needs and symptoms of their patients in a breast cancer outpatient consultation. Jpn J Clin Oncol 41:1251–1258
Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB (2011) Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol 12:1053–1061
Osuch JR, Silk K, Price C, Barlow J, Miller K, Hernick A, Fonfa A (2012) A historical perspective on breast cancer activism in the United States: from education and support to partnership in scientific research. J Womens Health (Larchmt) 21:355–362
Ou SH, Ziogas A, Zell JA (2009) Prognostic factors for survival in extensive stage small cell lung cancer (ED-SCLC): the importance of smoking history, socioeconomic and marital statuses, and ethnicity. J Thorac Oncol 4:37–43
Owonikoko TK, Ragin C, Chen Z, Kim S, Behera M, Brandes JC, Saba NF, Pentz R, Ramalingam SS, Khuri FR (2013) Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. Oncologist 18:600–610
Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F (2010) International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 102:456–463
Parker PA, Aaron J, Baile WF (2009) Breast cancer: unique communication challenges and strategies to address them. Breast J 15:69–75
Pass HI, Carbone DP, Johnson DH, Minna JD, Scagliotti GV, Turrisi AT (2010) Principles and practice of lung cancer. Lippincott Williams & Wilkins, Philadelphia
Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, De LM, Gilbert MR, Kris MG, Marshall JL, Masters GA, O’Day SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ (2014) Clinical cancer advances 2013: annual report on progress against cancer from the American society of clinical oncology. J Clin Oncol 32:129–160
Pentheroudakis G, Fountzilas G, Kalofonos HP, Golfinopoulos V, Aravantinos G, Bafaloukos D, Papakostas P, Pectasides D, Christodoulou C, Syrigos K, Economopoulos T, Pavlidis N (2008) Palliative chemotherapy in elderly patients with common metastatic malignancies: a Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol 66:237–247
Peppercorn JM, Smith TJ, Helft PR, Debono DJ, Berry SR, Wollins DS, Hayes DM, Von Roenn JH, Schnipper LE (2011) American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 29:755–760
Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R (2000) Smoking, smoking cessation, and lung cancer in the UK since 1950. BMJ 321:323–329
Pirie K, Peto R, Reeves GK, Green J, Beral V (2013) The 21st century hazards of smoking and benefits of stopping: a prospective study of one million women in the UK. Lancet 381:133–141
Pitz MW, Musto G, Demers AA, Kliewer EV, Navaratnam S (2009) Survival and treatment pattern of non-small cell lung cancer over 20 years. J Thorac Oncol 4:492–498
Planchard D, Le PC (2011) Small cell lung cancer: new clinical recommendations and current status of biomarker assessment. Eur J Cancer 47(Suppl 3):S272–S283
Puts MTE, Tu HA, Tourangeau A, Howell D, Fitch M, Springall E, Alibhai SMH (2014) Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol 25:564–577
Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61:91–112
SEER (2013) SEER Cancer Stat Fact Sheets, 2003–2009. National Cancer Institute. http://seer.cancer.gov/statfacts. Accessed 20 Dec 2013
Shepherd FA, Crowley J, Van HP, Postmus PE, Carney D, Chansky K, Shaikh Z, Goldstraw P (2007) The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2:1067–1077
Slotman BJ, Mauer ME, Bottomley A, Faivre-Finn C, Kramer GW, Rankin EM, Snee M, Hatton M, Postmus PE, Collette L, Senan S (2008) Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms–results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 22:3770–3776
Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, Ferrell BR, Loscalzo M, Meier DE, Paice JA, Peppercorn JM, Somerfield M, Stovall E, Von Roenn JH (2012) American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 30:880–887
Steele R, Fitch MI (2008) Why patients with lung cancer do not want help with some needs. Support Care Cancer 16:251–259
Stryker JE, Emmons KM, Viswanath K (2007) Uncovering differences across the cancer control continuum: a comparison of ethnic and mainstream cancer newspaper stories. Prev Med 44:20–25
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742
Tishelman C, Lovgren M, Broberger E, Hamberg K, Sprangers MA (2010) Are the most distressing concerns of patients with inoperable lung cancer adequately assessed? A mixed-methods analysis. J Clin Oncol 28:1942–1949
Townsley CA, Selby R, Siu LL (2005) Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 23:3112–3124
Tumorregister MĂĽnchen (2013) Basisstatistiken C50: Mammakarzinom (Frauen). http://www.tumorregister-muenchen.de. Accessed 22 Mar 2014
Ufen MP, Kohne CH, Wischneswky M, Wolters R, Novopashenny I, Fischer J, Constantinidou M, Possinger K, Regierer AC (2014) Metastatic breast cancer: are we treating the same patients as in the past? Ann Oncol 25:95–100
Vainio A, Auvinen A (1996) Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 12:3–10
van Vliet LM, van der Wall E, Plum NM, Bensing JM (2013) Explicit prognostic information and reassurance about nonabandonment when entering palliative breast cancer care: findings from a scripted video-vignette study. J Clin Oncol 31:3242–3249
Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D (2012) Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616–1625
Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S (2001) The prevalence of psychological distress by cancer site. Psychooncology 10:19–28
Zhong C, Liu H, Jiang L, Zhang W, Yao F (2013) Chemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One 8:e58466
Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A, Moore M, Rydall A, Rodin G, Tannock I, Donner A, Lo C (2014) Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 383(9930):1721–1730
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Frickhofen, N. (2015). Oncological and Palliative Care for Patients with Lung Cancer and Patients with Breast Cancer: Two Opposite Ends of a Spectrum. In: Alt-Epping, B., Nauck, F. (eds) Palliative Care in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46202-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-662-46202-7_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46201-0
Online ISBN: 978-3-662-46202-7
eBook Packages: MedicineMedicine (R0)